Drug-Eluting Stents for the Treatment of Intracranial Atherosclerosis.

Completed

Phase N/A Results

Eligibility Criteria

Inclusion Criteria

Patients who were treated with DES for symptomatic, severe (>70%) intracranial atherostenosis, and who had failed standard medical therapy with a combination of antithrombotic agents.